210 related articles for article (PubMed ID: 24926087)
1. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.
Clark BZ; Beriwal S; Dabbs DJ; Bhargava R
Am J Clin Pathol; 2014 Jul; 142(1):64-71. PubMed ID: 24926087
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
3. Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy.
Russell DH; Epstein JI; Kryvenko ON; Schlumbrecht M; Jorda M; Pinto A
Arch Pathol Lab Med; 2024 Jun; 148(6):705-714. PubMed ID: 37948107
[TBL] [Abstract][Full Text] [Related]
4. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder.
Ellis CL; Chang AG; Cimino-Mathews A; Argani P; Youssef RF; Kapur P; Montgomery EA; Epstein JI
Am J Surg Pathol; 2013 Nov; 37(11):1756-60. PubMed ID: 24061521
[TBL] [Abstract][Full Text] [Related]
5. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
[TBL] [Abstract][Full Text] [Related]
6. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
7. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.
Miyamoto H; Izumi K; Yao JL; Li Y; Yang Q; McMahon LA; Gonzalez-Roibon N; Hicks DG; Tacha D; Netto GJ
Hum Pathol; 2012 Nov; 43(11):2033-40. PubMed ID: 22607700
[TBL] [Abstract][Full Text] [Related]
8. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
10. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.
Siddiqui MT; Seydafkan S; Cohen C
Diagn Cytopathol; 2014 Sep; 42(9):809-15. PubMed ID: 24578300
[TBL] [Abstract][Full Text] [Related]
11. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
12. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
Ramalingam P; Middleton LP; Tamboli P; Troncoso P; Silva EG; Ayala AG
Ann Diagn Pathol; 2003 Apr; 7(2):112-9. PubMed ID: 12715337
[TBL] [Abstract][Full Text] [Related]
13. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
14. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
Esheba GE; Longacre TA; Atkins KA; Higgins JP
Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
[TBL] [Abstract][Full Text] [Related]
15. GATA3 Expression in Common Gynecologic Carcinomas: A Potential Pitfall.
Terzic T; Mills AM; Zadeh S; Atkins KA; Hanley KZ
Int J Gynecol Pathol; 2019 Sep; 38(5):485-492. PubMed ID: 30059453
[TBL] [Abstract][Full Text] [Related]
16. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin.
Bezerra SM; Lotan TL; Faraj SF; Karram S; Sharma R; Schoenberg M; Bivalacqua TJ; Netto GJ
Hum Pathol; 2014 Aug; 45(8):1682-7. PubMed ID: 24925221
[TBL] [Abstract][Full Text] [Related]
17. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
18. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
19. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
20. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
